Loading...
•
Dec 31, 2020
Corvus Pharmaceuticals Q4 2020 Earnings Report
Corvus Pharmaceuticals reported financial results and provided a business update.
Key Takeaways
Corvus Pharmaceuticals reported a net income of $27.1 million for the fourth quarter of 2020, with cash, cash equivalents, and marketable securities totaling $44.3 million as of December 31, 2020. The company is focused on advancing its clinical programs, including a Phase 3 study of CPI-006 for COVID-19.
Expanded technology platform to address COVID-19 and other infectious diseases.
Initiated a Phase 3 study of CPI-006 for COVID-19 after robust antibody responses in Phase 1 study.
Co-founded Angel Pharmaceuticals in China to develop product candidates in the Chinese market.
Three mid-to-late stage programs may provide catalysts for the Company in the near-term.
Forward Guidance
Corvus expects full year 2021 net cash used in operating activities to be between $46 million and $48 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...